What types of leukemia can tazerestat treat and its applications?

Tazemetostat is a new type of targeted therapy drug, mainly used to target malignant diseases with EZH2 gene abnormalities, especially in relapsed or refractory follicular lymphoma (FL; Non-Hodgkin lymphoma) and epithelioid sarcoma (ES; soft tissue sarcoma) have shown good efficacy. EZH2 is an epigenetic regulator that plays an important role in cell proliferation and differentiation. Its mutations are closely related to the occurrence and development of various tumor types.

For relapsed and refractory follicular lymphoma, traditional treatment methods often have limited effects, and patients face a high risk of recurrence and treatment failure. The emergence of tarzeta has brought new hope to this field. Studies have shown that tazerestat can effectively inhibit the growth of EZH2 mutant cells and also has a certain therapeutic effect on EZH2 wild-type tumor cells, which gives patients more possibilities when choosing treatment options.

In addition, epithelioid sarcoma is a rare and aggressive tumor with relatively few treatments, and the application of tazerestat provides a new option for such patients. Whether for patients with EZH2 mutations or wild-type patients, tazerestat can improve patient prognosis by inhibiting tumor growth and spread.

In terms of usage, the recommended dose of tazerestat is800 mg, taken twice daily. This medication regimen is simple and easy to implement. Patients only need to take it orally on time without complicated dosing procedures. The duration of treatment is generally until disease progression or the patient develops unacceptable toxicity. This flexibility allows doctors to make adjustments based on the patient's specific situation, ensuring that the principles of individualized treatment are implemented.

Reference materials:https://www.tazverik.com/